Literature DB >> 27126888

Letter: The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults (Diabetes Metab J 2016;40:62-9).

Kyung Soo Kim1.   

Abstract

Entities:  

Year:  2016        PMID: 27126888      PMCID: PMC4853226          DOI: 10.4093/dmj.2016.40.2.171

Source DB:  PubMed          Journal:  Diabetes Metab J        ISSN: 2233-6079            Impact factor:   5.376


× No keyword cloud information.
Cystatin C is a more sensitive indicator of mild renal impairment and better estimates the glomerular filtration rate than serum creatinine [1]. Recently, cystatin C has been suggested to provide information beyond renal function. Several studies suggested that cystatin C is associated with obesity, atherosclerosis, insulin resistance, and hypertension [23]. Furthermore, in Western populations, elevated levels of serum cystatin C are associated with prediabetes or diabetes [456]. In this article entitled "The association of serum cystatin C with glycosylated hemoglobin in Korean adults," Sim et al. [7] evaluated the association between cystatin C and prevalence of diabetic conditions defined by glycosylated hemoglobin (HbA1c) levels in Korean adults. They described that higher levels of serum cystatin C are associated with an increased prevalence of diabetic conditions in Korean adults. Interestingly, the positive association between cystatin C and diabetic conditions was not significant in the multivariable models, and this result was consistent with a previous study [6]. Although the ethnic differences in this association are not fully understood, the association between cystatin C and diabetic conditions may be weaker in Asian populations compared to white populations. However, there are several issues that need to be discussed. First, Sabanayagam et al. [6] examined the association between serum cystatin C and prediabetes in non-obese United States adults. They examined 2,033 participants from the National Health and Nutrition Examination Survey 1999 to 2002, aged ≥20 years who were free of diabetes mellitus and chronic kidney disease. Compared to those with cystatin C in the lowest quartile (quartile 1), the multivariate odds ratio (OR) of prediabetes among those in the highest quartile (quartile 4) was 2.08 (95% confidence interval [CI], 1.09 to 3.97; P for trend=0.02). The interesting point was that an inverse association was observed between cystatin C and prediabetes in quartile 2 (OR, 0.58; 95% CI, 0.37 to 0.89). In subgroup analysis, this inverse association in quartile 2 was significant in men and other race-ethnicities. In this study, the relative risk of subjects in the group with the fourth serum cystatin C levels (fourth=1.0 mg/L) for the presence of diabetic conditions was significantly decreased compared to the lowest group (first <0.8 mg/L) in the multivariable model (OR, 0.61; 95% CI, 0.39 to 0.97; P=0.037). Furthermore, this inverse association was also significant in men (OR, 0.48; 95% CI, 0.26 to 0.88; P=0.019). These results are compatible with the aforementioned study [6] but the reason for inverse association remains unclear. Second, specific conditions such as severe anemia and diseases that change erythrocyte lifespan should be excluded. HbA1c has been proposed as a diagnostic tool to identify people with undiagnosed diabetes or those who are at risk of diabetes [8]. The HbA1c test is a very attractive test for the diagnosis of diabetes and prediabetes because it is easy, reproducible, and reflects the mean blood glucose levels over a period of time [89]. However, the HbA1c is affected not only by age and race but also by various diseases such as anemia, liver cirrhosis, and chronic kidney disease [10]. Analyzing the patients without diseases that can potentially affect HbA1c level would be more appropriate to evaluate the association between cystatin C and prevalence of diabetic conditions defined by HbA1c levels.
  10 in total

Review 1.  Current controversies in the use of haemoglobin A1c.

Authors:  M J L Hare; J E Shaw; P Z Zimmet
Journal:  J Intern Med       Date:  2012-02-14       Impact factor: 8.989

Review 2.  (2) Classification and diagnosis of diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

3.  Cystatin C concentration as a risk factor for heart failure in older adults.

Authors:  Mark J Sarnak; Ronit Katz; Catherine O Stehman-Breen; Linda F Fried; Nancy Swords Jenny; Bruce M Psaty; Anne B Newman; David Siscovick; Michael G Shlipak
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

4.  Serum cystatin C and prediabetes in non-obese US adults.

Authors:  Charumathi Sabanayagam; Tien Yin Wong; Jie Xiao; Anoop Shankar
Journal:  Eur J Epidemiol       Date:  2013-02-16       Impact factor: 8.082

5.  Serum cystatin C and the incidence of type 2 diabetes mellitus.

Authors:  K Sahakyan; K E Lee; A Shankar; R Klein
Journal:  Diabetologia       Date:  2011-03-05       Impact factor: 10.122

6.  Is serum cystatin-C a reliable marker for metabolic syndrome?

Authors:  Aude Servais; Philippe Giral; Maguy Bernard; Eric Bruckert; Gilbert Deray; Corinne Isnard Bagnis
Journal:  Am J Med       Date:  2008-05       Impact factor: 4.965

7.  International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 17.152

8.  Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study.

Authors:  Richard P Donahue; Saverio Stranges; Karol Rejman; Lisa B Rafalson; Jacek Dmochowski; Maurizio Trevisan
Journal:  Diabetes Care       Date:  2007-04-24       Impact factor: 19.112

9.  Relationship between body mass index and high cystatin levels among US adults.

Authors:  Anoop Shankar; Srinivas Teppala
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-07       Impact factor: 3.738

10.  The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults.

Authors:  Eun Hee Sim; Hye Won Lee; Hyun Ju Choi; Dong Wook Jeong; Seok Man Son; Yang Ho Kang
Journal:  Diabetes Metab J       Date:  2016-02       Impact factor: 5.376

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.